Linezolid for the Treatment of Infections Caused by Methicillin Resistant Staphylococcus Aureus in Japan
NCT ID: NCT00150332
Last Updated: 2011-05-10
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
24 participants
INTERVENTIONAL
2003-01-31
2006-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Linezolid Plus Standard of Care
NCT06958835
Skin Structure Infections With Suspected or Proven Methicillin-Resistant Staphylococcus Aureus (MRSA)
NCT00087490
Nosocomial Pneumonia With Suspected Or Proven Methicillin-Resistant Staphylococcus Aureus (MRSA)
NCT00084266
Linezolid for Treatment of Nontuberculous Mycobacterial Diseases
NCT03220074
Safety and Efficacy of BAY1192631 in Japanese Patients With Methicillin-resistant Staphylococcus Aureus (MRSA) Infections
NCT01967225
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
TREATMENT
NONE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
linezolid
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
16 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pfizer
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Pfizer
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pfizer CT.gov Call Center
Role: STUDY_DIRECTOR
Pfizer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Pfizer Investigational Site
Kamogawa, Chiba, Japan
Pfizer Investigational Site
Fukuoka, Fukuoka, Japan
Pfizer Investigational Site
Fukuoka, Fukuoka, Japan
Pfizer Investigational Site
Onga-gun, Fukuoka, Japan
Pfizer Investigational Site
Hiroshima, Hiroshima, Japan
Pfizer Investigational Site
Hiroshima, Hiroshima, Japan
Pfizer Investigational Site
Sappopro, Hokkaido, Japan
Pfizer Investigational Site
Sapporo, Hokkaido, Japan
Pfizer Investigational Site
Moriya, Ibaraki, Japan
Pfizer Investigational Site
Yokohama, Kanagawa, Japan
Pfizer Investigational Site
Kyoto, Kyoto, Japan
Pfizer Investigational Site
Isahaya, Nagasaki, Japan
Pfizer Investigational Site
Nagasaki, Nagasaki, Japan
Pfizer Investigational Site
Kurashiki, Okayama-ken, Japan
Pfizer Investigational Site
Kurashiki, Okayama-ken, Japan
Pfizer Investigational Site
Okayama, Okayama-ken, Japan
Pfizer Investigational Site
Okayama, Okayama-ken, Japan
Pfizer Investigational Site
Suita, Osaka, Japan
Pfizer Investigational Site
Iruma-gun, Saitama, Japan
Pfizer Investigational Site
Kodaira, Tokyo, Japan
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
A5951054
Identifier Type: -
Identifier Source: secondary_id
M12600067
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.